Compare FNWB & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | HOWL |
|---|---|---|
| Founded | 1923 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 64.5M |
| IPO Year | 2015 | 2021 |
| Metric | FNWB | HOWL |
|---|---|---|
| Price | $9.96 | $1.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.50 | $7.00 |
| AVG Volume (30 Days) | 29.6K | ★ 490.6K |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,052,000.00 | N/A |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $0.60 |
| 52 Week High | $12.10 | $2.38 |
| Indicator | FNWB | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 52.22 |
| Support Level | $9.80 | $0.96 |
| Resistance Level | $10.14 | $1.03 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 46.15 | 96.55 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.